Stockscreener 앱 받기
20.81
0.90%
-0.19
전일 마감가:
$21.00
열려 있는:
$21.01
하루 거래량:
96,260
Relative Volume:
1.07
시가총액:
$278.50M
수익:
$116.26M
순이익/손실:
$-11.08M
주가수익비율:
-26.29
EPS:
-0.7917
순현금흐름:
$1.04M
1주 성능:
-1.37%
1개월 성능:
+6.12%
6개월 성능:
+44.92%
1년 성능:
+128.93%
1일 변동 폭
$20.76
$21.50
1주일 범위
$20.13
$21.66
52주 변동 폭
$8.37
$22.88
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
20.81 | 285.59M | 116.26M | -11.08M | 1.04M | -0.7917 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | B. Riley Securities | Buy |
| 2024-11-01 | 재확인 | Barrington Research | Outperform |
| 2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 재개 | Stephens | Equal-Weight |
| 2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 개시 | Stephens | Overweight |
| 2021-07-16 | 개시 | UBS | Neutral |
| 2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
| 2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 개시 | BWS Financial | Sell |
| 2019-09-24 | 재확인 | Barrington Research | Outperform |
| 2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 재확인 | Barrington Research | Outperform |
| 2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why? - TradingView
Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know - Yahoo Finance
Anika Therapeutics, Inc. (ANIK) stock price, news, quote and history - Yahoo Finance Singapore
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO - Yahoo Finance
Understanding Momentum Shifts in (ANIK) - Stock Traders Daily
Anika Therapeutics Stock Price Forecast. Should You Buy ANIK? - StockInvest.us
ANIK (NASDAQ: ANIK) holder plans Form 144 sale of 16,864 shares - stocktitan.net
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Anika Therapeutics (NASDAQ:ANIK) Raised to Strong-Buy at Zacks Research - MarketBeat
Anika (ANIK) Q2 2026 Earnings Call Transcript - The Globe and Mail
Anika Therapeutics (ANIK) Insider Gary Fischetti Buys 2,000 Shar - GuruFocus
Anika Therapeutics (NASDAQ:ANIK) Director Purchases 1,000 Shares - MarketBeat
Anika Therapeutics (ANIK) director purchases 2,000 common shares in market buys - Stock Titan
Anika Therapeutics (ANIK) Dips 2.14% to $19.19 as Support Level Comes into FocusLiquidity Sweep - dars.gov.et
Anika Therapeutics Lifts Outlook After Margin Surge - TipRanks
Q1 2025 Anika Therapeutics Inc Earnings Call Transcript - GuruFocus
Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher Guidance - Yahoo Finance
Anika Therapeutics Gains 29%, Insider Trades Reap Benefit - Moomoo
Wall Street Zen Upgrades Anika Therapeutics (NASDAQ:ANIK) to Strong-Buy - MarketBeat
Anika Therapeutics expands Integrity implant reach with 3,300 U.S. procedures and international availability - Traders Union
Vanguard Capital Management (ANIK) discloses 4.95% beneficial stake in Anika Therapeutics - Stock Titan
B. Riley Adjusts Anika Therapeutics Price Target to $21 From $18, Maintains Buy Rating - Moomoo
B. Riley Securities Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Raises Target Price to $21 - Moomoo
Anika Therapeutics (ANIK) Surges 7.8%: Technical Breakout in MotionPut Flow Alert - vinanet.vn
Anika Therapeutics Q2 2026 slides: margins surge, guidance raised By Investing.com - Investing.com Nigeria
Anika Therapeutics Inc (ANIK) Q2 2026 Earnings Call Highlights: - GuruFocus
Is Anika Therapeutics Inc (ANIK) On The Rise After Q2 Earnings B - GuruFocus
Anika Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Transcript : Anika Therapeutics, Inc., Q2 2026 Earnings Call, Jul 29, 2026 - marketscreener.com
Anika Therapeutics Q2 revenue rises 16% to $32.6 million - Quiver Quantitative
Anika: Q2 Earnings Snapshot - KING5.com
BRIEF-Anika Therapeutics Q2 Revenue USD 32.61 Million - TradingView
ANIK|Anika Therapeutics Inc|Price:15.010|Chg%:+0.060 - TradingKey
Anika Therapeutics Inc (ANIK) Balance Sheet - TradingKey
Anika Therapeutics Inc (ANIK) Income Statement - TradingKey
Anika Therapeutics Inc (ANIK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANIK|Anika Therapeutics Inc|Price:15.030|Chg%:+0.010 - TradingKey
Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anika Therapeutics Inc (ANIK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anika Therapeutics Inc (ANIK) Cash Flow - TradingKey
Anika Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Anika Therapeutics, Inc. Revenue Breakdown – BX:AKP - TradingView
Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Anika Therapeutics Q1 2026 Earnings: Strong EPS Beat Driven by Operational EfficienciesFree Cash Flow Trends - dars.gov.et
Anika Therapeutics (ANIK) 2026 CG Musculoskeletal Conference Summary - Quartr
Anika Therapeutics (ANIK) Proxy filing Summary - Quartr
Anika Therapeutics (ANIK) Q4 2025 earnings summary - Quartr
Anika Therapeutics (ANIK) AGM 2026 Summary - Quartr
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anika Therapeutics Inc 주식 (ANIK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fischetti Gary P | Director |
Aug 03 '26 |
Buy |
20.75 |
1,000 |
20,745 |
53,015 |
| Fischetti Gary P | Director |
Aug 04 '26 |
Buy |
20.32 |
1,000 |
20,315 |
54,015 |
| HENNEMAN JOHN B III | Director |
May 01 '26 |
Buy |
14.66 |
5,000 |
73,320 |
54,871 |
| Griffin Stephen D. | President and CEO |
Apr 30 '26 |
Buy |
12.29 |
12,200 |
149,881 |
36,163 |
1.66%
0.33%
자본화:
|
볼륨(24시간):